The best use of chemotherapy in the adjuvant setting

被引：9

作者：

Cardoso, F ^{[1
]}

Piccart, MJ ^{[1
]}

机构：

[1] Inst Jules Bordet, Dept Med Oncol, B-1000 Brussels, Belgium

来源：

BREAST | 2003年 / 12卷 / 06期

关键词：

breast; chemotherapy; adjuvant; anthracyclines; taxanes;

D O I：

10.1016/S0960-9776(03)00161-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Currently, based on the results of large randomized clinical trials and the conclusions of the Oxford meta-analysis (EBCTCG. Lancet 1998; 352: 930; Peto R. Fifth Main Meeting of the Early Breast Cancer Trialist's Collaborative Group, Oxford, UK, September 2000) and following internationally accepted treatment guidelines (National Institutes of Health Consensus Development Panel. J Natl Cancer Inst 2001; 93(13): 979; Goldhirsch et al. J Clin Oncol 2001; 19: 3817), the vast majority of primary breast cancer patients is offered adjuvant medical therapy. Regarding adjuvant chemotherapy (CT), the two most important and challenging tasks of the medical oncologist today are (1) to identify who needs CT and (2) to select the CT regimen that will work best for the individual patient, while at the same time minimizing the risk of severe or permanent toxicities. The second question will be the focus of this paper. (C) 2003 Elsevier Ltd. All rights reserved.

引用

页码：522 / 528

页数：7

共 37 条

[1]

Abe O, 1998, LANCET, V352, P930

[2] Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors:: 5-year follow-up results of French adjuvant study group 05 randomized trial [J].

Adenis, A ;

Bonneterre, J ;

Bonneterre, ME ;

Pion, JM ;

Vanlemmens, L ;

Gladieff, L ;

de Lafontan, B ;

Martel, P ;

Mihura, J ;

Roché, H ;

Gédouin, D ;

Kerbrat, P ;

Lesimple, T ;

Brémond, A ;

Devaux, Y ;

Delecroix, V ;

Fumoleau, P ;

Maugard-Louboutin, C ;

Namer, M ;

Goudier, MJ ;

Morice, F ;

Montcuquet, P ;

Schraub, S ;

Coudert, B ;

Fargeot, P ;

de Gislain, C ;

Mayer, F ;

Bastit, P ;

Chevallier, B ;

Grandgirard, A ;

Monnier, A ;

Sun, X ;

Clavère, P ;

Ollivier, JP ;

Rhein, B ;

Roullet, B ;

Datchary, J ;

Audhuy, B ;

Barats, JC ;

Kohser, F ;

Dides, S ;

Ramos, R ;

Cattan, A ;

Eymard, JC ;

Pourny, C ;

Weber, B ;

de Laroche, G ;

Pichon, A ;

Seffert, P ;

Hayat, M .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (03) :602-611

[3]

Bernard-Marty Chantal, 2002, Clin Breast Cancer, V3, P341, DOI 10.3816/CBC.2002.n.037

[4]

BONNETERRE J, 1998, P AN M AM SOC CLIN, V17, pA124

[5]

BREMOND A, 1996, P AN M AM SOC CLIN, V15, P113

[6] Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer [J].

Budman, DR ;

Berry, DA ;

Cirrincione, CT ;

Henderson, IC ;

Wood, WC ;

Weiss, RB ;

Ferree, CR ;

Muss, HB ;

Green, MR ;

Norton, L ;

Frei, E .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (16) :1205-1211

[7]

Buzdar AU, 2002, CLIN CANCER RES, V8, P1073

[8] Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancer [J].

Cardoso, F ;

Di Leo, A ;

Piccart, MJ .

CANCER TREATMENT REVIEWS, 2002, 28 (06) :275-290

[9]

CARDOSO F, 2002, AM J CANC, V1, P257

[10] Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/cancer and leukemia group B trial 9741 [J].

Citron, ML ;

Berry, DA ;

Cirrincione, C ;

Hudis, C ;

Winer, EP ;

Gradishar, WJ ;

Davidson, NE ;

Martino, S ;

Livingston, R ;

Ingle, JN ;

Perez, EA ;

Carpenter, J ;

Hurd, D ;

Holland, JF ;

Smith, BL ;

Sartor, CI ;

Leung, EH ;

Abrams, J ;

Schilsky, RL ;

Muss, HB ;

Norton, L .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1431-1439

← 1 2 3 4 →